Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4575893 | 0.95 | SLC28A1 (0.53) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| Phosphoric Acid SCHEMBL20769291 | 0.95 | SLC28A1 (0.53) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL7876363 | 0.93 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL8749574 | 0.93 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL1763360 | 0.93 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL233416 | 0.93 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| Hydrochloric Acid SCHEMBL29938288 | 0.92 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL17439383 | 0.86 | POLA1 (0.60) | POLA1P2RY2P2RY4P2RY14P2RY6 | |
| Phosphoric Acid SCHEMBL21751466 | 0.85 | SLC29A1 (0.55) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL17184312 | 0.84 | PDE3A (0.67) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | ACHILLION PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016986-A1 | STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT | NUDT1, DUT, ADAR | SLC29A1 51/4885SLC28A1 130/4885SLC28A2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.